New Stock News | Vivomix Bio submits application to Hong Kong Stock Exchange

According to the disclosure from the Hong Kong Stock Exchange on February 13th, WEMabiolife Biotechnology (Zhejiang) Co., Ltd. - B (referred to as WEMabiolife) has submitted its listing application to the Main Board of the Hong Kong Stock Exchange, with CICC as its exclusive sponsor. According to the prospectus, the company has two core products, VVN461 (high dose) and VVN001. VVN461 (high dose) is a high-dose formulation of VVN461 eye drops, a new Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) selective dual target inhibitor, with potency reaching subnanomolar levels. As of the last practicable date (February 5, 2026), in addition to the company's core products, the company has six other candidate drugs, three of which are in clinical stages. The company was established in 2016 and is a biotechnology company focusing on the field of ophthalmology, committed to becoming a global leader in innovative ophthalmic therapy research and commercialization.